Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Symbol: 
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
04/25/20242:00AMGlobeNewswire Inc.VAALCO Schedules First Quarter 2024 Earnings Release and Conference CallLSE:EGYVaalco Energy Inc.
04/25/20242:00AMGlobeNewswire Inc.Boussard & Gavaudan Holding Ltd (EUR): Annual Report and Audited Financial StatementsLSE:BGHLBoussard & Gavaudan Holding Limited
04/25/20242:00AMGlobeNewswire Inc.Boussard & Gavaudan Holding Ltd (EUR): Annual Report and Audited Financial Statements NSMLSE:BGHLBoussard & Gavaudan Holding Limited
04/25/20242:00AMGlobeNewswire Inc.Boussard & Gavaudan Holding Ltd (GBP): Annual Report and Audited Financial StatementsEU:BGHSBoussard and Gavaudan Holding
04/25/20242:00AMBusiness WireACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke TreatmentEU:ALACTActicor Biotech
04/25/20242:00AMBusiness WireAGM Trading Update - April 2024
04/25/20242:00AMGlobeNewswire Inc.Irish Residential Properties Sub-Fund 1: Form 8.3 - Irish Residential Properties REIT PLC
04/25/20242:00AMGlobeNewswire Inc.GALISMMO SCA Entité française du groupe Galimmo Real Estate - Information financière au 31 mars 2024EU:GALIMGalimmo
04/25/20242:00AMGlobeNewswire Inc.GALISMMO SCA Entité française du groupe Galimmo Real Estate - Information financière au 31 mars 2024LSE:0F6FGalimmo Sa
04/25/20242:00AMBusiness WireQ1 2024 resultsNASDAQ:AZNAstraZeneca PLC
04/25/20242:00AMGlobeNewswire Inc.Subsea 7 S.A. Announces First Quarter 2024 ResultsTG:SOCSubsea 7 SA
04/25/20242:00AMGlobeNewswire Inc.Galantas Report Annual Financial Results for the Year Ended December 31, 2023TSXV:GALGalantas Gold Corporation
04/25/20242:00AMGlobeNewswire Inc.Hermès International : Chiffre d'affaires du 1er trimestre 2024TG:HMIHermes International
04/25/20242:00AMGlobeNewswire Inc.Boussard & Gavaudan Holding Ltd (EUR): Annual Report and Audited Financial Statements NSMEU:BGHLBoussard And Gavaudan Holding Limited
04/25/20242:00AMGlobeNewswire Inc.Boussard & Gavaudan Holding Ltd (GBP): Annual Report and Audited Financial StatementsLSE:BGHSBoussard & Gavaudan Holding Limited
04/25/20242:00AMGlobeNewswire Inc.Boussard & Gavaudan Holding Ltd (EUR): Annual Report and Audited Financial StatementsEU:BGHLBoussard And Gavaudan Holding Limited
04/25/20242:00AMGlobeNewswire Inc.Boussard & Gavaudan Holding Ltd (GBP): Annual Report and Audited Financial Statements NSMEU:BGHSBoussard and Gavaudan Holding
04/25/20242:00AMGlobeNewswire Inc.Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
04/25/20242:00AMGlobeNewswire Inc.Sterling to Add Fixed Income Support to Risk & Margin Service
04/25/20242:00AMGlobeNewswire Inc.VAALCO Schedules First Quarter 2024 Earnings Release and Conference CallNYSE:EGYVaalco Energy Inc
04/25/20242:00AMGlobeNewswire Inc.Galantas Report Annual Financial Results for the Year Ended December 31, 2023AMEX:GALSPDR SSgA Global Allocation ETF
04/25/20242:00AMGlobeNewswire Inc.Boussard & Gavaudan Holding Ltd (GBP): Annual Report and Audited Financial Statements NSMLSE:BGHSBoussard & Gavaudan Holding Limited
04/25/20242:00AMBusiness WireACTICOR BIOTECH : Résultats principaux de l’étude de phase 2/3 ACTISAVE dans le traitement de l’AVCEU:ALACTActicor Biotech
04/25/20242:00AMGlobeNewswire Inc.Hermès International : Chiffre d'affaires du 1er trimestre 2024EU:RMSHermes International
04/25/20241:58AMBusiness WireRyan nommé parmi les Meilleurs lieux de travailMC au Canada pour la 12e année consécutive par Great Place to Work®
04/25/20241:54AMBusiness Wireオープンソース・データベースのリーダーPercona、リズ・ワーナーを最高技術責任者に任命
04/25/20241:53AMPR Newswire (US)Wanhua Chemical Launches Barcelona R&D Center, Unveiling Signified Focus and Commitment in Europe and Beyond
04/25/20241:52AMBusiness WireMundipharma erwirbt alle Vermögenswerte und Rechte an REZZAYO® (Rezafungin) und unterstreicht damit sein Engagement für das Management von Infektionskrankheiten und den Therapiebereich Spezialmedizin
04/25/20241:52AMBusiness WireMundipharma acquiert tous les actifs et droits liés à REZZAYO® (rézafungine), renforçant ainsi son engagement continu dans la gestion des maladies infectieuses et les soins spécialisés
04/25/20241:48AMAlliance NewsAlliance NewsLONDON MARKET EARLY CALL: Stocks called down ahead of US GDP data